Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SMTI Stock Forecast 2026-2027
$20.81
Current Price
$190.70M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SMTI Price Targets
+73.0%
To High Target of $36.00
+63.4%
To Median Target of $34.00
+53.8%
To Low Target of $32.00
SMTI Price Momentum
-7.3%
1 Week Change
-3.8%
1 Month Change
-27.8%
1 Year Change
-10.9%
Year-to-Date Change
-42.1%
From 52W High of $35.95
+29.7%
From 52W Low of $16.05
📊 TOP ANALYST CALLS
Did SMTI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sanara MedTech is one of their latest high-conviction picks.
Latest SMTI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, SMTI has a bullish consensus with a median price target of $34.00 (ranging from $32.00 to $36.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $20.81, the median forecast implies a 63.4% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Frank Takkinen at Lake Street, suggesting a 53.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SMTI Analyst Ratings
2
Buy
0
Hold
0
Sell
SMTI Price Target Range
Low
$32.00
Average
$34.00
High
$36.00
Current: $20.81
Latest SMTI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SMTI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2026 | Lake Street | Frank Takkinen | Buy | Initiates | $32.00 |
| Jan 26, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 14, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 18, 2025 | HC Wainwright& Co. | Buy | Maintains | $N/A | |
| May 15, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 26, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Mar 26, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 23, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jan 23, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 22, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Dec 23, 2024 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| May 15, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Mar 27, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Feb 6, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Nov 15, 2023 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Sep 26, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Aug 22, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Aug 17, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jun 30, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A |
Sanara MedTech Inc. (SMTI) Competitors
The following stocks are similar to Sanara MedTech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SMTI
Sanara MedTech
mkt cap
205.64M
Sanara MedTech Inc. (SMTI) Financial Data
Sanara MedTech Inc. has a market capitalization of $190.70M with a P/E ratio of 358.3x. The company generates $107.48M in trailing twelve-month revenue with a -31.2% profit margin.
Revenue growth is +18.6% quarter-over-quarter, while maintaining an operating margin of +9.5% and return on equity of +2.9%.
Valuation Metrics
Market Cap
$190.70M
Enterprise Value
$245.44M
P/E Ratio
358.3x
PEG Ratio
-3.2x
Price/Sales
1.8x
Growth & Margins
Revenue Growth (YoY)
+18.6%
Gross Margin
+93.1%
Operating Margin
+9.5%
Net Margin
-31.2%
EPS Growth
+18.6%
Financial Health
Cash/Price Ratio
+7.1%
Current Ratio
2.3x
Debt/Equity
689.0x
ROE
+2.9%
ROA
+8.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sanara MedTech Inc. (SMTI) Business Model
About Sanara MedTech Inc.
What They Do
Develops advanced wound care products and technologies.
Business Model
Sanara MedTech operates in the healthcare sector, generating revenue by collaborating with healthcare providers, hospitals, and outpatient facilities to supply innovative wound care products. Their offerings include antimicrobial dressings and collagen-based solutions that enhance healing and reduce infection risks.
Additional Information
The company's focus on research and development allows it to stay ahead in medical innovation, addressing significant challenges in wound management. Sanara MedTech plays a crucial role in enhancing patient outcomes and improving quality of life, positioning itself as a key player in the growing market for effective wound care solutions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
108
CEO
Mr. Seth D. Yon
Country
United States
IPO Year
1995
Website
sanaramedtech.comSanara MedTech Inc. (SMTI) Latest News & Analysis
Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI
23 days ago
Quick Summary
Pomerantz LLP is investigating claims for investors of Sanara MedTech, Inc. (NASDAQ: SMTI). Interested parties can contact Danielle Peyton for more information.
Why It Matters
Investigation into Sanara MedTech may indicate potential legal issues, affecting stock performance and investor confidence in the company.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Sanara MedTech Inc. (SMTI) held its Q1 2026 earnings call, discussing financial performance and strategic initiatives. Details on revenue and future outlook were addressed.
Why It Matters
The Q1 2026 earnings call for Sanara MedTech Inc. provides insights into financial performance and strategic direction, impacting stock valuation and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Sanara MedTech reported Q1 2026 revenue growth of 19% and achieved its first GAAP profit in years. Operating margins exceed 10%, with 2026 revenue guidance of $116M–$121M.
Why It Matters
Sanara MedTech's strong Q1 2026 results and strategic focus on high-return segments signal improved profitability and growth potential, bolstering investor confidence despite recent stock gains.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
The company reported a 19% increase in net revenue and a net profitability of $0.04 per fully diluted share for the quarter.
Why It Matters
Strong net revenue growth and positive profitability indicate robust business performance, potentially leading to increased investor confidence and stock value appreciation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SMTI Investors Have Opportunity to Join Sanara MedTech Inc. Fraud Investigation with the Schall Law Firm
1 month ago
Quick Summary
The Schall Law Firm is investigating Sanara MedTech Inc. (NASDAQ: SMTI) for potential securities law violations, including possible false statements affecting investors.
Why It Matters
The investigation into Sanara MedTech for potential securities law violations may lead to legal liability and affect the company's stock price, impacting investor confidence and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ICON is trading at a low double-digit free cash flow multiple, below historical averages. S&P Global's services are crucial amid growth in private credit and AI. Sanara Medtech shows strong product efficacy and growth potential.
Why It Matters
ICON's low valuation suggests potential for upside as market underestimates its growth and business strength. Sanara Medtech's product efficacy and market strategy indicate strong future performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About SMTI Stock
What is Sanara MedTech Inc.'s (SMTI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Sanara MedTech Inc. (SMTI) has a median price target of $34.00. The highest price target is $36.00 and the lowest is $32.00.
Is SMTI stock a good investment in 2026?
According to current analyst ratings, SMTI has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SMTI stock?
Wall Street analysts predict SMTI stock could reach $34.00 in the next 12 months. This represents a 63.4% increase from the current price of $20.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sanara MedTech Inc.'s business model?
Sanara MedTech operates in the healthcare sector, generating revenue by collaborating with healthcare providers, hospitals, and outpatient facilities to supply innovative wound care products. Their offerings include antimicrobial dressings and collagen-based solutions that enhance healing and reduce infection risks.
What is the highest forecasted price for SMTI Sanara MedTech Inc.?
The highest price target for SMTI is $36.00 from at , which represents a 73.0% increase from the current price of $20.81.
What is the lowest forecasted price for SMTI Sanara MedTech Inc.?
The lowest price target for SMTI is $32.00 from Frank Takkinen at Lake Street, which represents a 53.8% increase from the current price of $20.81.
What is the overall SMTI consensus from analysts for Sanara MedTech Inc.?
The overall analyst consensus for SMTI is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $34.00.
How accurate are SMTI stock price projections?
Stock price projections, including those for Sanara MedTech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 2:49 PM UTC